ライフサイエンスコーパス: transthyretin

1 erence (RNAi) could reduce the production of transthyretin.

2 hibits amyloid formation by both WT and L55P transthyretin.

3 raction between RBP4 and its binding partner transthyretin.

4 c fragment of the disease-associated protein transthyretin.

5 biophysical properties to recombinant human transthyretin.

6 expression of the liver markers albumin and transthyretin.

7 in light chain, serum amyloid A protein, and transthyretin.

8 ain mass spectra of the noncovalent tetramer transthyretin.

9 europathy were identified, 60 primary and 41 transthyretin.

10 tion of the beta-Amyloid Peptide Abeta42 and transthyretin.

11 n in the peripheral nervous system of mutant transthyretin.

12 y-binding to the thyroxine-carrying protein, transthyretin.

13 In preeclampsia, the serum levels of transthyretin, a carrier protein for thyroxine, are elev

14 etroaldolase, a de novo designed enzyme, and transthyretin, a nonenzyme protein.

15 Herein, we provide evidence that transthyretin, a transporter of thyroxine and retinol, i

16 eover, the treatment increased expression of transthyretin, accompanied by reduction of intracellular

17 in vitro, even though in [PSI+] cells NM and transthyretin aggregates also occasionally colocalize.

18 s and Schwann cells of nerves with deposited transthyretin aggregates but the pattern also extended t

19 We demonstrate that transthyretin aggregates form deposits in preeclampsia p

20 Transthyretin aggregation-associated proteotoxicity appe

21 regates of non-polyQ amyloidogenic proteins, transthyretin, alpha-synuclein, and synphilin do not.

22 Hereditary transthyretin amyloid (ATTR) amyloidosis is a rare but f

23 in a reticular/pericellular pattern, whereas transthyretin amyloid (ATTR) more commonly showed patchy

24 All 6 patients had wild-type transthyretin amyloid (mean age 75 years; range, 69-85;

25 o reactivity to the Abeta precursor protein, transthyretin amyloid aggregates, or irrelevant proteins

26 Paradoxical acceleration of transthyretin amyloid deposition following OLT may occur

27 resulting from aggregation and deposition of transthyretin amyloid fibrils in various tissues.

28 s study explored the prevalence of wild-type transthyretin amyloid in cAS by myocardial biopsy, its i

29 used by the deposition of hepatocyte-derived transthyretin amyloid in peripheral nerves and the heart

30 s has been followed by turbidity to identify transthyretin amyloidogenesis inhibitors including diben

31 The transthyretin amyloidoses (ATTR) are invariably fatal di

32 The transthyretin amyloidoses appear to be caused by rate-li

33 Transthyretin amyloidosis (ATTR) is a heterogeneous diso

34 Cardiac transthyretin amyloidosis (ATTR) is an increasingly reco

35 Hereditary transthyretin amyloidosis (ATTR) is usually characterise

36 tion (LTx) has been performed for hereditary transthyretin amyloidosis (ATTR) since 1990.

37 mically to bind human AA, ALkappa, ALlambda, transthyretin amyloidosis (ATTR), and Abeta amyloid depo

38 for cardiac light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR).

39 Heart failure caused by wild-type transthyretin amyloidosis (ATTRwt) is an underappreciate

40 In univariable analyses, the presence of transthyretin amyloidosis amyloid had the highest hazard

41 epidemiology, and therapeutic strategies for transthyretin amyloidosis and highlight diagnostic pitfa

42 kilogram of body weight) in 32 patients with transthyretin amyloidosis and then evaluated ALN-TTR02 (

43 Here, we describe a series of transthyretin amyloidosis inhibitors that functioned by

44 Transthyretin amyloidosis is a fatal disorder that is ch

45 Transthyretin amyloidosis is a rare, life-threatening di

46 Transthyretin amyloidosis is caused by the deposition of

47 Treatment of transthyretin amyloidosis is typically focused on sympto

48 United States by using data from the THAOS (Transthyretin Amyloidosis Outcomes Survey) registry.

49 of small molecules proposed as inhibitors of transthyretin amyloidosis were shown to be effective in

50 who when compared with whites with wild-type transthyretin amyloidosis, a phenotypically similar cond

51 For patients with transthyretin amyloidosis, there are numerous therapies

52 eported as the cause of the life-threatening transthyretin amyloidosis.

53 was informative in only 40% of patients with transthyretin amyloidosis.

54 esidues 105-115 of the amyloidogenic protein transthyretin and a DNA origami construct is used to for

55 Furthermore, transthyretin and alpha-synuclein amyloids do not facili

56 In all beta-sheet proteins, transthyretin and beta(2)-microglobulin, alpha-pleated s

57 11-residue peptide derived from the protein transthyretin and clusters of this fibre-forming peptide

58 ant APP possess high levels of sAPPalpha and transthyretin and do not develop the tau phosphorylation

59 the disassociation of the tetrameric form of transthyretin and favor the formation of amyloid fibers.

60 loidogenesis, we produced recombinant murine transthyretin and human/murine transthyretin heterotetra

61 y showed that the placenta actively produces transthyretin and in preeclampsia, a significant amount

62 rate that the sAPPalpha-driven expression of transthyretin and insulin-like growth factor 2 is necess

63 here were 28 patients (25 men) with Ala97Ser transthyretin and late onset (59.9 +/- 6.0 years) disabl

64 dence for a causal link between dysregulated transthyretin and preeclampsia.

65 olipoproteins, complement C4-A, haptoglobin, transthyretin and serotransferrin.

66 4 patients: 5 amyloid light chain, 5 amyloid transthyretin, and 4 control with hypertensive heart dis

67 he plasma proteins, fibrinogen, fibronectin, transthyretin, and alpha-fetoprotein, an essential featu

68 tetrameric protein complexes (streptavidin, transthyretin, and hemoglobin) in the gas phase was unde

69 in three unrelated amyloid species: Abeta42, transthyretin, and human islet amylin polypeptide.

70 e case of those formed from serum amyloid A, transthyretin, and islet amyloid polypeptide.

71 mon systemic amyloidoses (ALlambda, ALkappa, transthyretin, and reactive amyloidosis), with Congo red

72 rin, tissue inhibitor of metalloproteases-1, transthyretin, and the transcription factor C/EBPdelta.

73 n techniques with primers designed to detect transthyretin, apolipoprotein AI, apolipoprotein AII, fi

74 stability of dimer and tetramer formation of transthyretin as a function of pH.

75 (Transthyretin-Associated Amyloidoses Outcome Survey [THA

76 Cardiac transthyretin (ATTR) amyloidosis is a progressive and fa

77 oidosis, immunoglobulin light chain (AL) and transthyretin (ATTR) amyloidosis, are substantially infl

78 onoclonal immunoglobulin light-chain (AL) or transthyretin (ATTR) type-and healthy volunteers (n = 5)

79 e C, holo hemoglobin-alpha, ovalbumin, human transthyretin, avidin, bovine serum albumin, concanavali

80 Transthyretin, beta(2)-microglobulin, lysozyme, and the

81 d qRT-PCR, we investigated the production of transthyretin by preeclamptic placentae and whether tran

82 id systems, beta-amyloid peptide (Abeta) and transthyretin, by these designed alpha-sheet peptides.

83 Occult wild-type transthyretin cardiac amyloid had a prevalence of 6% amo

84 Wild-type transthyretin cardiac amyloid is also a disorder of agei

85 Importance: Transthyretin cardiac amyloidosis (also known as ATTR ca

86 Transthyretin cardiac amyloidosis (ATTR) is an underreco

87 Wild-type transthyretin cardiac amyloidosis (ATTRwt) is increasing

88 st common of these conditions, but wild-type transthyretin cardiac amyloidosis (ATTRwt) is increasing

89 primarily affects the peripheral nerves, and transthyretin cardiomyopathy (TTR-CM), which primarily a

90 ongoing phase 3 ATTR-ACT study (Tafamidis in Transthyretin Cardiomyopathy Clinical Trial), an interna

91 Compared to primary cases, transthyretin cases had longer survival, longer time to

92 Twenty transthyretin cases were found to have Val30Met mutation

93 old, found in many proteins belonging to the Transthyretin clan of Pfam.

94 c placentae secreted similar levels of total transthyretin compared to normotensive placentae (2352 +

95 plasma concentrations, whereas the ratio of transthyretin-Cys10-S-S-cysteine to that of unmodified t

96 The ratios of transthyretin-Cys10-S-S-homocysteine and transthyretin-C

97 Transthyretin-Cys10-S-S-homocysteine was then identified

98 en is thus reflected in the plasma levels of transthyretin-Cys10-S-S-homocysteine, which in turn may

99 of transthyretin-Cys10-S-S-homocysteine and transthyretin-Cys10-S-S-sulfonate to that of unmodified

100 tin-Cys10-S-S-cysteine to that of unmodified transthyretin decreased.

101 These observations explain the lack of transthyretin deposition in transgenics carrying a low c

102 Moreover, when preventing nonfibrillar transthyretin deposition with anakinra or transthyretin

103 PhosphorImaging, two bands corresponding to transthyretin dimer and tetramer were observed.

104 egulated in cancer); (b) a truncated form of transthyretin (down-regulated); and (c) a cleavage fragm

105 n proposed based on precursor stabilization (transthyretin), elimination of the synthesizing cell (li

106 uction of both mutant and nonmutant forms of transthyretin, establishing proof of concept for RNAi th

107 ed proteins (Abeta peptides, prion proteins, transthyretin, etc.) to aggregate and form fibrils.

108 neuropathy (SFN) is an important feature of transthyretin familial amyloid polyneuropathy (TTR-FAP).

109 Transthyretin familial amyloid polyneuropathy is a hered

110 een shown to delay neurologic progression of transthyretin familial amyloid polyneuropathy, there are

111 ate phenotypic presentations of the disease: transthyretin familial amyloid polyneuropathy, which pri

112 IBG imaging is a useful prognostic marker in transthyretin familial amyloid polyneuropathy.

113 etic denervation detected by MIBG imaging in transthyretin familial amyloid polyneuropathy.

114 nates more than 95% of variant amyloidogenic transthyretin from the circulation.

115 We determined genotype status for the transthyretin gene (TTR) in 3856 black participants in t

116 A novel mutation in the transthyretin gene (TTR) in Indian patients with familia

117 eaving enzyme), ApoE (apolipoprotein E), and transthyretin gene expression were unchanged with the hi

118 Silencing the murine transthyretin gene in the presence of the L55P human gen

119 siRNAs are being explored to knock-down the transthyretin gene to prevent the related form of amyloi

120 he noncovalently associated complex of human transthyretin, generated by collision-induced dissociati

121 nsgenics carrying a low copy number of human transthyretin genes.

122 The aggregation of transthyretin has been reported as the cause of the life

123 These findings suggest that transthyretin has earlier and greater predilection for n

124 binant murine transthyretin and human/murine transthyretin heterotetramers and compared their structu

125 PP, neprilysin, insulin-degrading enzyme and transthyretin in MCAT, AbetaPP, MCAT/AbetaPP and wild-ty

126 The increased aggregation of transthyretin in preeclampsia occurs at the post-transcr

127 ion of retinol-binding protein 4 (RBP4) with transthyretin in the serum would reduce serum RBP4 and r

128 in-Cys10-S-S-sulfonate to that of unmodified transthyretin increased with increasing homocysteine pla

129 fferent sources (alpha-synuclein, Sup35, and transthyretin) induced NADPH oxidase-dependent NETs in v

130 Native transthyretin inhibits all preeclampsia-like features in

131 critical conformational changes at the RBP4-transthyretin interface.

132 Chronic infusion of an antibody against transthyretin into the hippocampus of mice overexpressin

133 P) associated with mutations in the gene for transthyretin is a rare, progressively disabling and ult

134 We found that the sequestering agent transthyretin is able to bind the toxic Abeta(1-42) spec

135 yretin by preeclamptic placentae and whether transthyretin is carried into the maternal circulation v

136 Therefore, the elevated expression of transthyretin is mediated by sAPPalpha and protects APP(

137 Murine transthyretin is not amyloidogenic because the native ho

138 Transthyretin is produced predominantly in the liver, an

139 ecursor proteins, including serum amyloid A, transthyretin, islet amyloid polypeptide, and amyloid be

140 Transthyretin isolated from preeclamptic serum is also a

141 in 3xTg-AD mice and increasing expression of transthyretin, known to inhibit Abeta aggregation.

142 For ALN-TTR02, the mean reductions in transthyretin levels at doses of 0.15 to 0.3 mg per kilo

143 pid, dose-dependent, and durable lowering of transthyretin levels was observed in the two trials.

144 phase 1 trial to assess safety and effect on transthyretin levels.

145 We show here that the monomeric transthyretin-like domain of human carboxypeptidase D ag

146 n of BRI1 identified an Arabidopsis thaliana Transthyretin-Like protein (TTL) as a potential BRI1 sub

147 common Greek-key beta sandwich fold with two transthyretin-like repeats that polymerize into a pilus

148 nts included urinary protein 1 (m/z=15,835), transthyretin (m/z=13,880), and a component at m/z=13,35

149 rtitioning of destabilized retroaldolase and transthyretin mutants between the aforementioned conform

150 A total of 143 individuals with V30M transthyretin mutation underwent Holter, ambulatory bloo

151 ly variable and influenced by the underlying transthyretin mutation, age of the affected individual,

152 Val122Ile is the most common transthyretin mutation, and neurologic phenotypic expres

153 arterial pressure, but not the presence of a transthyretin mutation, were independently associated wi

154 c failure and is due to dominantly inherited transthyretin mutations causing accelerated amyloid depo

155 in amyloidosis without typical signs, senile transthyretin, or hereditary amyloidosis with a concomit

156 wing targets will be specifically discussed: transthyretin, p53, superoxide dismutase 1, lysozyme, se

157 titrypsin, complement factor B, haptoglobin, transthyretin, plasma retinol binding protein, albumin,

158 The amyloidogenic protein transthyretin (prealbumin), as we now report, undergoes

159 hat the murine protein interacted with human transthyretin, preventing the dissociation and partial u

160 e mutations, under the control of the murine transthyretin promoter, were generated and crossed with

161 TG mice expressed rat IL-10 downstream of a transthyretin promoter, which led to serum levels that w

162 ox8 is the Xenopus homolog of Pdx1, the TTR (transthyretin) promoter directs expression to the liver,

163 arallel phagocytic pathway that includes the transthyretin protein TTR-52, as well as CED-7, NRF-5 an

164 ne-to-isoleucine substitution (V122I) in the transthyretin protein, which has been associated with la

165 reditary amyloidosis associated with variant transthyretin proteins, which are mainly synthesized in

166 tiating immunoglobulin light-chain (AL) from transthyretin-related cardiac amyloidoses (ATTR) is impe

167 Transthyretin-related cardiac amyloidosis is a progressi

168 monomer unfolding of the human serum protein transthyretin, resulting in aggregation and extracellula

169 ement, recombinant thyroid transport protein transthyretin (rTTR), and dedicated modes of liquid chro

170 Conservative mutation of transthyretin's surface residues can predispose an indiv

171 Detailed analyses have been described for transthyretin (senile systemic amyloidosis and familial

172 e to aggregation and deposition of wild-type transthyretin (senile systemic amyloidosis, SSA) or mono

173 C, prenylcysteine oxidase 1, paraoxonase 1, transthyretin, serum amyloid A4, and fibrinogen alpha ch

174 ar transthyretin deposition with anakinra or transthyretin siRNA, Pcdh10 protein levels were reduced,

175 Our findings suggest that a focus on transthyretin structure and function is a novel strategy

176 rs otherwise composed of human amyloid-prone transthyretin subunits imposes kinetic stability, preven

177 s of two protein complexes, source-activated transthyretin tetramer and nativelike serum amyloid P de

178 his fashion and is an excellent inhibitor of transthyretin tetramer dissociation and amyloidogenesis,

179 tion approach was applied to generate intact transthyretin tetramers with charge states ranging from

180 enta, they may also be delivering aggregated transthyretin to specific maternal organs, contributing

181 residue segment of the amyloidogenic protein transthyretin (TTR(105-115)).

182 e synthesized and evaluated as inhibitors of transthyretin (TTR) aggregation, including amyloid fibri

183 sion of the human systemic amyloid precursor transthyretin (TTR) ameliorates Alzheimer's disease (AD)

184 It is well established that the formation of transthyretin (TTR) amyloid fibrils is linked to the des

185 ulfated GAGs, especially heparin, accelerate transthyretin (TTR) amyloidogenesis by quaternary struct

186 Transthyretin (TTR) amyloidogenesis inhibitors are typic

187 To develop potent transthyretin (TTR) amyloidogenesis inhibitors that also

188 To develop potent and highly selective transthyretin (TTR) amyloidogenesis inhibitors, it is us

189 Transthyretin (TTR) amyloidogenesis requires rate-limiti

190 Transthyretin (TTR) amyloidogenesis requires rate-limiti

191 Transthyretin (TTR) amyloidoses are familial or sporadic

192 The transthyretin (TTR) amyloidoses are human diseases in wh

193 LTx) is an accepted treatment for hereditary transthyretin (TTR) amyloidosis (ATTR).

194 Transthyretin (TTR) amyloidosis is a progressive systemi

195 g transcriptional profiling, we now identify transthyretin (TTR) and Klotho as APP/APLP2-dependent ge

196 g retinol levels, which are located near the transthyretin (TTR) and retinol binding protein 4 (RBP4)

197 gating oligomerization and ligand binding of transthyretin (TTR) and the chaperone domain from prosur

198 ed via parallel, high-throughput analysis of transthyretin (TTR) and transferrin (TRFE) from 96 ident

199 either wild-type (ATTRwt) or mutant (ATTRm) transthyretin (TTR) CA.

200 Wild-type and mutant transthyretin (TTR) can misfold and deposit in the heart

201 th retinoids for RBP4 binding, disrupts RBP4-transthyretin (TTR) complexes, and results in urinary se

202 on studies were carried out as a function of transthyretin (TTR) concentration to quantify the thermo

203 (14 kDa) identified by mass spectroscopy as transthyretin (TTR) consistently correlated with BBBD.

204 promotes degradation of the nonglycosylated transthyretin (TTR) D18G misfolded client.

205 strate that mammalian cells secrete numerous transthyretin (TTR) disease-associated variants with wil

206 ommon familial amyloid polyneuropathy (FAP), transthyretin (TTR) displays this role primarily affecti

207 Five groups of patients were studied: (1) transthyretin (TTR) familial amyloidotic polyneuropathy

208 The tetrameric thyroxine transport protein transthyretin (TTR) forms amyloid fibrils upon dissociat

209 Transthyretin (TTR) forms misfolded beta-sheet aggregate

210 of valine for isoleucine at codon 122 of the transthyretin (TTR) gene (V122I), present in 3.43% of Af

211 dominant disorder caused by mutations in the transthyretin (TTR) gene; however, carriers of the same

212 ition of fibrils and amorphous aggregates of transthyretin (TTR) in patient tissues is a hallmark of

213 caused by aggregation of Ig light chains or transthyretin (TTR) in the cardiac interstitium and cond

214 ion of retinol-binding protein 4 (RBP4) with transthyretin (TTR) in the serum may decrease the uptake

215 rgeting human apolipoprotein C-III and human transthyretin (TTR) in transgenic mice.

216 of a GalNAc conjugate duplex targeting mouse transthyretin (TTR) indicated that GNA is well tolerated

217 Transthyretin (TTR) is a blood and cerebrospinal fluid t

218 Circulating transthyretin (TTR) is a critical determinant of plasma

219 Transthyretin (TTR) is a homotetramer that circulates in

220 Transthyretin (TTR) is a homotetrameric protein.

221 Transthyretin (TTR) is a homotetrameric transport protei

222 Transthyretin (TTR) is a largely beta-sheet serum protei

223 Transthyretin (TTR) is a plasma homotetrameric protein i

224 Transthyretin (TTR) is a thyroxine-transport protein fou

225 Human transthyretin (TTR) is an amyloidogenic protein whose ag

226 Transthyretin (TTR) is an amyloidogenic protein, the amy

227 Human transthyretin (TTR) is an amyloidogenic protein.

228 nt of l-thyroxine (T4) from binding sites on transthyretin (TTR) is considered a significant contribu

229 Kinetic stabilization of transthyretin (TTR) is established to prevent human neur

230 The visceral protein transthyretin (TTR) is frequently affected by oxidative

231 The human systemic amyloid precursor protein transthyretin (TTR) is known to inhibit amyloid-beta (Ab

232 The plasma protein transthyretin (TTR) is linked to human amyloidosis.

233 Transthyretin (TTR) is normally a stable plasma protein.

234 Transthyretin (TTR) is one of the many proteins that are

235 Wild type transthyretin (TTR) is responsible for senile systemic a

236 The amyloidogenic protein transthyretin (TTR) is thought to aggregate into amyloid

237 Increased neuronal synthesis of transthyretin (TTR) may favorably impact on Alzheimer's

238 in younger patients with the most prevalent transthyretin (TTR) Met30 variant, who have mild symptom

239 The process of transthyretin (TTR) misfolding and aggregation, includin

240 ained in this fashion because wild-type (WT) transthyretin (TTR) misfolds and misassembles into amylo

241 The amyloidogenic homotetrameric protein transthyretin (TTR) must undergo rate-limiting dissociat

242 The homotetrameric protein transthyretin (TTR) must undergo rate-limiting dissociat

243 Over 70 transthyretin (TTR) mutations facilitate amyloidosis in

244 asymptomatic individuals with amyloidogenic transthyretin (TTR) mutations.

245 ramer dissociation and monomer misfolding of transthyretin (TTR) occur before its aggregation into cr

246 ntaining amyloid deposits composed of either transthyretin (TTR) or Ig light chain from nine patients

247 The Ser52Pro variant of transthyretin (TTR) produces aggressive, highly penetran

248 ransgenic (TG) mouse line in which the -3-kb transthyretin (TTR) promoter functioned to increase hepa

249 s with familial amyloidosis, mutation in the transthyretin (TTR) protein is the most common type.

250 Acidification of the transthyretin (TTR) tetramer facilitates dissociation an

251 Each subunit of the transthyretin (TTR) tetramer has a single Cys residue th

252 Dissociation of the native transthyretin (TTR) tetramer is widely accepted as the c

253 The ability of transthyretin (TTR) to bind Abeta-peptides and the posit

254 In turn, holo-RBP associates in plasma with transthyretin (TTR) to form a ternary RBP-retinol-TTR co

255 nd vinyl sulfonamides that covalently modify transthyretin (TTR) tracelessly.

256 ection in vivo, overexpression of a WT human transthyretin (TTR) transgene was ameliorative in the AP

257 y for the inner thyroxine binding subsite of transthyretin (TTR) was conceived of by structure-based

258 sis is caused by an amyloidogenic variant of transthyretin (TTR) with a substitution of methionine fo

259 This is the case of transthyretin (TTR), a homotetrameric protein whose diss

260 e previously studied the amyloidogenicity of transthyretin (TTR), a human beta-sheet-rich homotetrame

261 ATTR are caused by aggregation of transthyretin (TTR), a natively tetrameric protein invol

262 Transthyretin (TTR), a systemic amyloid precursor in the

263 pete with thyroxin (T4) for binding sites on transthyretin (TTR), a T4 transport protein found in pla

264 roid hormone disrupting chemicals (THDCs) is transthyretin (TTR), a thyroid hormone transporter in ve

265 itive genes, alpha1-antitrypsin (alpha1-AT), transthyretin (TTR), and apolipoprotein B (ApoB) after i

266 protein complexes: C-reactive protein (CRP), transthyretin (TTR), and concanavalin A (Con A).

267 protein-protein interaction between RBP4 and transthyretin (TTR), another serum protein that protects

268 ng the binding of 2,4-dinitrophenol (DNP) to transthyretin (TTR), as well as preliminary measurements

269 the conformation of model proteins, namely, transthyretin (TTR), avidin, concanavalin A (conA), and

270 ic amyloidoses caused by mutant or wild-type transthyretin (TTR), deposition occurs at a distance fro

271 The misfolding of transthyretin (TTR), including rate-limiting tetramer di

272 The misfolding of transthyretin (TTR), including rate-limiting tetramer di

273 Wild-type transthyretin (TTR), normally a soluble plasma-circulati

274 yloid fibril formation by the plasma protein transthyretin (TTR), requiring rate-limiting tetramer di

275 We determined the transthyretin (TTR)-binding activity of blood-accumulati

276 Compounds with transthyretin (TTR)-binding potency in the blood plasma

277 mice were crossbred with the liver-specific transthyretin (TTR)-IGF-I transgenic mice to assess the

278 4-oxadiazole designed to bind selectively to transthyretin (TTR).

279 c" (ATTR) variants from mutant and wild-type transthyretin (TTR).

280 increase in the expression of TTR, encoding transthyretin (TTR).

281 f these chemicals is the hormone transporter transthyretin (TTR).

282 ) prion, and a short polypeptide fragment of transthyretin, TTR (105-115), directly correlates to the

283 eptide fragment of the amyloidogenic protein transthyretin, TTR(105-115), in its fibrillar form, dete

284 ted Phase II/III trials for the treatment of Transthyretin Type Familial Amyloid Polyneuropathy (TTR-

285 d in 76 patients, including 56 with the wild transthyretin type, 17 with the mutant transthyretin typ

286 wild transthyretin type, 17 with the mutant transthyretin type, and 3 with the secondary type.

287 nuclein associated with Parkinson's disease, transthyretin V30M mutant associated with familial amylo

288 sgenic for few copies of amyloid-prone human transthyretin variants, including the aggressive L55P mu

289 actors that include properties of particular transthyretin variants, nutritional status, age, severit

290 Thus, when human plasma or highly purified transthyretin was incubated with 35S-L-homocysteine foll

291 of knockdown of the clinically relevant gene transthyretin was observed at doses as low as 0.03 mg/kg

292 f HPR with retinol binding protein (RBP) and transthyretin was studied by spectrofluorometry and size

293 01); levels of mutant and nonmutant forms of transthyretin were lowered to a similar extent.

294 Both total and aggregated transthyretin were present in higher levels in preeclamp

295 Increased levels of aggregated transthyretin were specifically associated to preeclampt

296 ins (all except BSA) and an impurity (bovine transthyretin) were confidently identified by database s

297 s, two peptides (serum amyloid A protein and transthyretin) were identified and quantitated by immuno

298 euritogenesis with a decreased expression of transthyretin, which is known to be downregulated by oxi

299 of 1.0 mg per kilogram, ALN-TTR01 suppressed transthyretin, with a mean reduction at day 7 of 38%, as

300 amyloid polyneuropathy (FAP) due to mutated transthyretin, with sudomotor failure as a common manife